Cantor Fitzgerald issued research notes on Gilead Sciences (GILD) stock, which are being aggregated by MarketBeat.
1 report, 1 independent
Updated Jun 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald issued research notes on Gilead Sciences (GILD) stock, which are being aggregated by MarketBeat.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
Cantor Fitzgerald
American financial services company
-
MarketBeat
American personal finance blog
Related events
- Cantor Fitzgerald increased its price target and rating for Hyperliquid Strategies, while MarketBeat provided consensus rating data.
- Cantor Fitzgerald provided research reports on Cabaletta Bio, a company whose stock trades on Nasdaq.
- MarketBeat aggregated analyst reports on Best Buy stock on September 13, 2026.
- Cantor Fitzgerald decreased its price objective for BitMine Immersion Technologies Inc. while MarketBeat provided consensus rating data.
- Cantor Fitzgerald raised its price target and rating, while Bank of America adjusted its rating and price target, with MarketBeat aggregating the stock rating data.